PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 78 Publications

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2358-2372

PubMed: 31461652 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

EMBO J, 2018, 37(1):19-38

PubMed: 29150432 ( click the link to review the publication )

PLoS Biol, 2018, 16(5):e2003619

PubMed: 29771909 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )
J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )

Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )
BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

J Clin Invest, 2013, 123(11):4786-98

PubMed: 24216509 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )
Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEKyO\|Yh\|ryP	MkixV2FPT0WU
CHP-212	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLyTWM2OD1yLkCyPFg2KM7:TR?=	NIfye5ZUSU6JRWK=
EoL-1-cell	NF3FOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfWTWM2OD1yLkC0NVUzKM7:TR?=	NGPYb3BUSU6JRWK=
DU-4475	M2OyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH3fYN3UUN3ME2wMlA4PTl7IN88US=>	NHjJcItUSU6JRWK=
MMAC-SF	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7FfpNsUUN3ME2wMlExQTd2IN88US=>	M2G5cHNCVkeHUh?=
AGS	M2PFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mom1TWM2OD1yLkGxO\|E{KM7:TR?=	NHqxR2RUSU6JRWK=
M14	M4XuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHrb3VrUUN3ME2wMlE2PDZ6IN88US=>	NYjRUVRwW0GQR1XS
CP50-MEL-B	NGexcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMUeyOVQh\|ryP	NFzwV3ZUSU6JRWK=
C32	M3Xnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL3VHBKSzVyPUCuNVkxPzJizszN	Ml33V2FPT0WU
KMOE-2	M3HZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX3XXZtUUN3ME2wMlE6Pzl3IN88US=>	Mk\XV2FPT0WU
A101D	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\hZlFKSzVyPUCuNlE1KM7:TR?=	NGi5eFRUSU6JRWK=
KM12	NFnidoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf0TWM2OD1yLkK0NFU4KM7:TR?=	NWPYXnAyW0GQR1XS
HSC-4	M1LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfEdIxVUUN3ME2wMlI1Ozl3IN88US=>	NYDIOXVZW0GQR1XS
NOMO-1	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvLTWM2OD1yLkK1O\|QzKM7:TR?=	NE\EXYFUSU6JRWK=
MZ7-mel	NFHvZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LxO2lEPTB;MD6yOlM1KM7:TR?=	MkjIV2FPT0WU
ACN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XKPWlEPTB;MD6yOlc{PyEQvF2=	NIWzcJBUSU6JRWK=
MEL-HO	M4TBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr4VI5JUUN3ME2wMlI4PjV{IN88US=>	NHfyZVFUSU6JRWK=
BHT-101	NHPQU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHuTWM2OD1yLkK4OlA3KM7:TR?=	MWPTRW5ITVJ?
SK-MEL-28	NXLqbVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLzSWdCUUN3ME2wMlMxPDB7IN88US=>	Ml7GV2FPT0WU
KG-1	NHm5eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrOTWM2OD1yLkOwOlY5KM7:TR?=	NV:zNG1LW0GQR1XS
COLO-679	NHPyPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwM{K3NkDPxE1?	MYTTRW5ITVJ?
SK-MEL-24	NID0NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO5e\|RyUUN3ME2wMlMzQDF\|IN88US=>	MWLTRW5ITVJ?
G-361	NFHUOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwM{[3PVUh\|ryP	NHnNVIpUSU6JRWK=
KY821	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfqdVZKSzVyPUCuN\|c6OSEQvF2=	M1j2TXNCVkeHUh?=
KASUMI-1	NFjTb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwM{m5JO69VQ>?	NFLy[I9USU6JRWK=
HL-60	M1XzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLKTWM2OD1yLkSxNVA4KM7:TR?=	NUjQc4h5W0GQR1XS
K5	M3LDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNEOxNVch\|ryP	MYLTRW5ITVJ?
KU812	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XqNmlEPTB;MD60OVI6QSEQvF2=	NF73OWtUSU6JRWK=
SH-4	M{DrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13QfGlEPTB;MD60OlI2PiEQvF2=	NFTkVnZUSU6JRWK=
HTC-C3	NVThfpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vue2lEPTB;MD60OlU{OSEQvF2=	MXvTRW5ITVJ?
CP66-MEL	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HjfGlEPTB;MD60PFgxQSEQvF2=	NEPFT4hUSU6JRWK=
WM-115	M1XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzPbJR[UUN3ME2wMlQ6OjV5IN88US=>	NXHuXGZjW0GQR1XS
A2780	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn6RYlFUUN3ME2wMlQ6QDJ\|IN88US=>	MYTTRW5ITVJ?
P12-ICHIKAWA	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;De4FKSzVyPUCuOlEzOjFizszN	MojpV2FPT0WU
HMV-II	M2K1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjFWWV[UUN3ME2wMlY1PDZ3IN88US=>	MYjTRW5ITVJ?
HT-144	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwNkS2OVch\|ryP	NV;ZWZNqW0GQR1XS
LB2518-MEL	M3fM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\1TWM2OD1yLkexOlMzKM7:TR?=	NWPvRYE1W0GQR1XS
NCI-SNU-1	NWXNbYVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwN{W0N\|Mh\|ryP	NVvlTZB4W0GQR1XS
C2BBe1	M1u1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\qc2tKSzVyPUCuPFExOjNizszN	NYHCXHBLW0GQR1XS
PSN1	NFjXNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwOU[xPVYh\|ryP	MVfTRW5ITVJ?
UACC-257	NV7NVI13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwOU[0O\|Mh\|ryP	NGHI[YFUSU6JRWK=
RVH-421	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1qxdGlEPTB;MD65O\|E5KM7:TR?=	M2fn[3NCVkeHUh?=
GP5d	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwOUizNFgh\|ryP	NFHKPI1USU6JRWK=
TYK-nu	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT4UW9ZUUN3ME2xMlA{OTd{IN88US=>	M{DKZXNCVkeHUh?=
SK-N-AS	NH3wUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFwMEe5OFch\|ryP	MljBV2FPT0WU
SW620	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnje4MxUUN3ME2xMlE{PTN2IN88US=>	NVL0WGFkW0GQR1XS
HuP-T4	NVvreHRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojhTWM2OD1zLkG4N\|U6KM7:TR?=	NVq1OVFvW0GQR1XS
A549	NIjNenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTITWM2OD1zLkG5OVc3KM7:TR?=	NGHTTIdUSU6JRWK=
Mewo	NEC1RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknrTWM2OD1zLkKwNlc3KM7:TR?=	MkT4V2FPT0WU
ONS-76	NHLIVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\Xd2E1UUN3ME2xMlIzODR7IN88US=>	MYjTRW5ITVJ?
SK-MEL-1	M1fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPld2pHUUN3ME2xMlI{PDF7IN88US=>	MkTsV2FPT0WU
RCM-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPJNWw3UUN3ME2xMlI1ODR5IN88US=>	MofxV2FPT0WU
H-EMC-SS	NGjZS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwMkm2NFgh\|ryP	MkHBV2FPT0WU
NCI-H2291	NHW0XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7sNZZsUUN3ME2xMlMzPTN4IN88US=>	NFruZ5NUSU6JRWK=
SW1463	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTFOolKSzVyPUGuN\|M4OjFizszN	MV\TRW5ITVJ?
LS-411N	NIfzVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HJS2lEPTB;MT60NFUyPyEQvF2=	NUf4Z4tCW0GQR1XS
BV-173	M1T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULDVYNmUUN3ME2xMlQ1ODF3IN88US=>	MVHTRW5ITVJ?
LS-513	NUGwRlNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFwNEWxPVIh\|ryP	NUDYcGJHW0GQR1XS
LoVo	NIWzVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPLU2JKSzVyPUGuOFY{QTlizszN	MYXTRW5ITVJ?
HO-1-N-1	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHtTWM2OD1zLkWxOlM1KM7:TR?=	MXfTRW5ITVJ?
ML-2	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LKSWlEPTB;MT61Nlg3QCEQvF2=	NX;EU\|F5W0GQR1XS
NCI-H1437	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\3TINDUUN3ME2xMlU2Ojd3IN88US=>	NG\0NmJUSU6JRWK=
SW1116	NVjVSnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3PTWM2OD1zLkW2N\|k5KM7:TR?=	MYTTRW5ITVJ?
A4-Fuk	M{TN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnG3TWM2OD1zLkW3NFQ2KM7:TR?=	M2q0d3NCVkeHUh?=
HD-MY-Z	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zobmlEPTB;MT61O\|M4PiEQvF2=	NVznVXZZW0GQR1XS
SK-MEL-2	NFnNfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwNUe0OVkh\|ryP	MWDTRW5ITVJ?
RT-112	NYPGVmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTFwNUi5OVIh\|ryP	MlPkV2FPT0WU
COLO-829	NYT5SWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwNkKyN\|Ih\|ryP	NV;sS5g4W0GQR1XS
OVCAR-5	NWPWbnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTmS3dRUUN3ME2xMlc4Pjh5IN88US=>	MlrNV2FPT0WU
NB69	M1;XRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T3VmlEPTB;MT63PFQ3QSEQvF2=	MkSwV2FPT0WU
NCI-H292	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwOE[2PVkh\|ryP	M{f5[HNCVkeHUh?=
LOXIMVI	NWfxZ4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwOEm0Nlch\|ryP	M37lcXNCVkeHUh?=
BPH-1	NHPmcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlr3TWM2OD1zLki5OVkyKM7:TR?=	M3XoNHNCVkeHUh?=
A375	M13CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELpUnlKSzVyPUGuPFk4OTRizszN	M371UnNCVkeHUh?=
LCLC-97TM1	M4G4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXh[HlKSzVyPUGuPVIzPTZizszN	MXLTRW5ITVJ?
RXF393	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlSyTWM2OD1zLkm3PFg4KM7:TR?=	M3LBUnNCVkeHUh?=
HCC70	NXi0V3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPnZZZKSzVyPUKuNFI1OjZizszN	MmTYV2FPT0WU
EM-2	NHXsfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIex[GJKSzVyPUKuNFcyQThizszN	Mk\uV2FPT0WU
MZ2-MEL	M1fsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LRZmlEPTB;Mj6xNVEzPyEQvF2=	NVm4Wo1xW0GQR1XS
HN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD5TXRWUUN3ME2yMlE3Ojd6IN88US=>	NXvTT2hUW0GQR1XS
A2058	MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HWWGlEPTB;Mj6xPVI4QSEQvF2=	MVfTRW5ITVJ?
NB7	NGC0SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJwM{SwPFYh\|ryP	MoPOV2FPT0WU
DOK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13lNmlEPTB;Mj6zOVc4OyEQvF2=	MmiyV2FPT0WU
CAL-27	NWq2SoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJwM{myN\|Yh\|ryP	NWDvPYQzW0GQR1XS
BB65-RCC	M1;Ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TMR2lEPTB;Mj60NFY4PCEQvF2=	MnjvV2FPT0WU
RD	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLKV2kzUUN3ME2yMlQ1PzJ\|IN88US=>	MXrTRW5ITVJ?
KNS-62	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rUdmlEPTB;Mj61NVE3PCEQvF2=	M17qOXNCVkeHUh?=
EW-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\5TWM2OD1{LkW2N\|M6KM7:TR?=	MXHTRW5ITVJ?
DB	M33qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PaNmlEPTB;Mj61PFc5QCEQvF2=	M1zjU3NCVkeHUh?=
HCC2218	NYDnS3drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlT5TWM2OD1{Lk[0O\|c5KM7:TR?=	NX;2bIdOW0GQR1XS
L-363	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTJwN{SzO{DPxE1?	NV[wUpNxW0GQR1XS
CHL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLWS4x{UUN3ME2yMlgxPzh3IN88US=>	NFXmbIRUSU6JRWK=
BFTC-905	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrkfo1KSzVyPUKuPFI2OyEQvF2=	M3jDOXNCVkeHUh?=
HCE-T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJwOEOyOlQh\|ryP	MmnJV2FPT0WU
COLO-792	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTJwOESwNlch\|ryP	MX7TRW5ITVJ?
LB2241-RCC	NHj5ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT6TWM2OD1{Lki1PFk{KM7:TR?=	NXi0c5VwW0GQR1XS
CAL-39	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELtSlFKSzVyPUKuPFk6QTlizszN	MnXmV2FPT0WU
T-24	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJwOUGxNVIh\|ryP	M3zRc3NCVkeHUh?=
NCI-H727	M3\MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;zTWM2OD1{LkmxO\|k3KM7:TR?=	NYC3VmplW0GQR1XS
Ca9-22	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHSzTohKSzVyPUKuPVczPTVizszN	MWXTRW5ITVJ?
MIA-PaCa-2	NV\k[I1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm0T3JKSzVyPUOuNFA4QDFizszN	MmPhV2FPT0WU
HT-1080	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfXbmVKSzVyPUOuNFE6QTdizszN	NFnKPFVUSU6JRWK=
D-423MG	NGe1SoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInkUZFKSzVyPUOuNFc4PTNizszN	MlLKV2FPT0WU
LAMA-84	NXGwd49LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rzemlEPTB;Mz6xN\|U5KM7:TR?=	M1rtZ3NCVkeHUh?=
SW780	M1rCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO1PHNKSzVyPUOuNVQzOjlizszN	NYf1c3BjW0GQR1XS
KU-19-19	NIjmXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTNwMUewN\|Qh\|ryP	MkfhV2FPT0WU
COLO-741	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K5PWlEPTB;Mz6xPFY4OyEQvF2=	MUnTRW5ITVJ?
HSC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXyTWM2OD1\|LkKzNVUyKM7:TR?=	MWPTRW5ITVJ?
SN12C	NEKzXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrz[2Z[UUN3ME2zMlI1PzBzIN88US=>	M3;FXXNCVkeHUh?=
786-0	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTNwMkeyOFMh\|ryP	MVPTRW5ITVJ?
GAK	M1TPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTNwM{K1OlEh\|ryP	NHTWcodUSU6JRWK=
PANC-03-27	M2j5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XpcmlEPTB;Mz6zOVA1PSEQvF2=	NXLGTWV6W0GQR1XS
CTB-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\0dGlEPTB;Mz60O\|A1PyEQvF2=	MUjTRW5ITVJ?
A427	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf1dFlbUUN3ME2zMlU6PTV4IN88US=>	NWW0TnVDW0GQR1XS
EGI-1	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTNwNkC1PFMh\|ryP	Mn;zV2FPT0WU
U-2-OS	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\HTWM2OD1\|Lk[3NlU3KM7:TR?=	M1fOfHNCVkeHUh?=
NCI-SNU-5	NWrSRZhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzXTWM2OD1\|Lk[3O\|Mh\|ryP	NX\h[lNzW0GQR1XS
SK-LU-1	NXvJ[2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNwNki3PVgh\|ryP	MVnTRW5ITVJ?
697	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGC2N\|dKSzVyPUOuOlk3ODNizszN	NFHIflFUSU6JRWK=
HPAF-II	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLUWnl[UUN3ME2zMlc2PDlizszN	M3zPc3NCVkeHUh?=
NCI-H2087	NV\QTFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLqTWM2OD1\|Lki0OlczKM7:TR?=	MYDTRW5ITVJ?
SK-MEL-3	NEDx[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTQO\|RKSzVyPUOuPFUyPTRizszN	NFfDb5NUSU6JRWK=
CGTH-W-1	NWXrTmNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;oTWM2OD1\|Lki1O\|I2KM7:TR?=	M{DZdnNCVkeHUh?=
8505C	NEGxN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK3N3VKSzVyPUOuPVAxPzhizszN	M1vjOXNCVkeHUh?=
GAMG	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PFbGlEPTB;ND6wNlM4PyEQvF2=	MmC4V2FPT0WU
SW626	NGKwOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjDUIFKSzVyPUSuNFQ1QCEQvF2=	M4LZenNCVkeHUh?=
CAL-62	NGCxXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHQe4JTUUN3ME20MlA4PDNizszN	MWTTRW5ITVJ?
MHH-PREB-1	NXHrfnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTRwMUKxNVEh\|ryP	NFGwUnRUSU6JRWK=
RPMI-7951	NXPFZ3NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2np[mlEPTB;ND6yOVU5QSEQvF2=	Mnr5V2FPT0WU
HOP-92	M13PU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;4TWM2OD12LkK1Olch\|ryP	NGTh[3VUSU6JRWK=
MDA-MB-231	M2rXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmOwTWM2OD12LkK5NlI{KM7:TR?=	NFzq[WlUSU6JRWK=
LAN-6	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfKSY1{UUN3ME20MlMyPjN5IN88US=>	MWfTRW5ITVJ?
ALL-PO	NFrXVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHDTWM2OD12LkO2NVU3KM7:TR?=	NILYcndUSU6JRWK=
HH	NF[weZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljUTWM2OD12LkSxOVk4KM7:TR?=	NYfQbVJZW0GQR1XS
IGROV-1	NVXscXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NES4XlVKSzVyPUSuOFUyPzFizszN	MmXxV2FPT0WU
NCI-H358	NV3GemJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTRwNEWzPFUh\|ryP	MXHTRW5ITVJ?
NB5	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWroU\|hQUUN3ME20MlYxOzZ7IN88US=>	MVrTRW5ITVJ?
NCI-H747	NFr4UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv6[W1KSzVyPUSuOlg5ODdizszN	MojzV2FPT0WU
NH-12	NVPvRpZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\YTHhQUUN3ME20MlcyPjJ3IN88US=>	Mn3XV2FPT0WU
LB1047-RCC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljnTWM2OD12LkezPFE2KM7:TR?=	NVXid4NOW0GQR1XS
EFO-27	M4HtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnHTWM2OD12Lke4OlY4KM7:TR?=	MV;TRW5ITVJ?
EPLC-272H	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LXe2lEPTB;ND65PVY3QSEQvF2=	M{npOXNCVkeHUh?=
CAL-54	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz2UFI5UUN3ME21MlAzPjl3IN88US=>	MYHTRW5ITVJ?
H4	M{H4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjMPZBKSzVyPUWuNFQzPTVizszN	NGP2XJZUSU6JRWK=
MOLT-13	M3rtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfORoY5UUN3ME21MlA3Pzd4IN88US=>	NWLjfmRwW0GQR1XS
CAL-33	NIPSeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTVwMUKzNVch\|ryP	M33kc3NCVkeHUh?=
23132-87	NEnZUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTVwMU[4O\|Ih\|ryP	NYG1VIJsW0GQR1XS
UM-UC-3	NWfWNZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnq1TWM2OD13LkG4NFQ4KM7:TR?=	M3m1SHNCVkeHUh?=
HuH-7	NVzLWZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TlXmlEPTB;NT6yO\|E1PyEQvF2=	MnTsV2FPT0WU
BCPAP	NUXH[G5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XaT2lEPTB;NT6zNlk3QSEQvF2=	M3f2SHNCVkeHUh?=
AsPC-1	M{jNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\WTXRKSzVyPUWuN\|Y4PjNizszN	M4T1S3NCVkeHUh?=
NCI-H1155	NWT1SZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTVwNECwOVEh\|ryP	MorRV2FPT0WU
GT3TKB	NGHxeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\2XXBKSzVyPUWuOFY2QThizszN	M4P6cnNCVkeHUh?=
HCC2998	NY\kepFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTVwNEmxNFkh\|ryP	M1rMR3NCVkeHUh?=
NUGC-3	NX3S[otYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrDNnJrUUN3ME21MlQ6OzB{IN88US=>	MoXiV2FPT0WU
Hs-578-T	NI\CWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXBPY4{UUN3ME21MlU{Pzl2IN88US=>	MUDTRW5ITVJ?
FADU	NHviWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfiXIpKSzVyPUWuOVU4OjZizszN	MYLTRW5ITVJ?
NBsusSR	NHvMdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnyO49KSzVyPUWuOVcyPTVizszN	MmC4V2FPT0WU
ME-180	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LPfmlEPTB;NT61PFA6OiEQvF2=	NHvUXYJUSU6JRWK=
SW1710	NHPnXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX4dFZKSzVyPUWuOlE3PTRizszN	MlWwV2FPT0WU
HuP-T3	NV7VboRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX5TWM2OD13Lk[yNFI6KM7:TR?=	MVPTRW5ITVJ?
HOS	NFvLe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHezbXpKSzVyPUWuOlI6OjNizszN	M3PyOXNCVkeHUh?=
PA-1	M1\CPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTVwNkSyOlUh\|ryP	M{SyNXNCVkeHUh?=
LU-99A	NWL4ZZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXHe3NKSzVyPUWuOlY1PTFizszN	MYHTRW5ITVJ?
RS4-11	NUe2Wm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLQd5hKSzVyPUWuOlY4PzVizszN	M4PaUnNCVkeHUh?=
TE-8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTt[JV7UUN3ME21MlY5PTN5IN88US=>	NYL4fVZMW0GQR1XS
RERF-LC-MS	NIPKSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfjT5JQUUN3ME21MlY5QDB\|IN88US=>	MWXTRW5ITVJ?
MEL-JUSO	NELRSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPF[ZlKSzVyPUWuO\|M4QCEQvF2=	M1rmVHNCVkeHUh?=
SK-MES-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz1U4YxUUN3ME21Mlg{PTJ6IN88US=>	M4POR3NCVkeHUh?=
D-263MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr3eolKSzVyPUWuPFg{PTFizszN	MW\TRW5ITVJ?
NB10	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorLTWM2OD13Lki5OFYh\|ryP	MUHTRW5ITVJ?
SK-HEP-1	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK3PINoUUN3ME21Mlk{PDdzIN88US=>	MUDTRW5ITVJ?
HT-29	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[zZ4FpUUN3ME21Mlk5OTF6IN88US=>	M13XV3NCVkeHUh?=
KYSE-140	M1PlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGixfJNKSzVyPU[uNFIyQDJizszN	MVXTRW5ITVJ?
NCI-H1666	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1z0b2lEPTB;Nj6wPFQ3OSEQvF2=	NUXwWI5zW0GQR1XS
NCI-H1304	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jS[WlEPTB;Nj6xPVk1KM7:TR?=	NF;FSoxUSU6JRWK=
RPMI-8866	M{LvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3FWlBKSzVyPU[uNlE{OTNizszN	M{j5OnNCVkeHUh?=
MV-4-11	M2\jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnrVoxkUUN3ME22MlI{OTl7IN88US=>	MU\TRW5ITVJ?
A431	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTZwMkSyPVYh\|ryP	NH3MdHhUSU6JRWK=
PANC-10-05	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTZwMkizOlMh\|ryP	MULTRW5ITVJ?
TK10	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfQWJE{UUN3ME22MlMzPjB2IN88US=>	NEPGO4hUSU6JRWK=
NCI-H1975	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTZwNEeyNVUh\|ryP	NES2VpZUSU6JRWK=
A172	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrZ[JhKSzVyPU[uOFkyPzZizszN	NEDMbpBUSU6JRWK=
D-566MG	M2K0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS0b5RKSzVyPU[uOVQ{ODNizszN	M1zz[HNCVkeHUh?=
NCI-H2122	NGXyNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfvXI5NUUN3ME22MlYyPTJ6IN88US=>	MWjTRW5ITVJ?
COR-L105	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTZwNkWyO\|Uh\|ryP	MVzTRW5ITVJ?
AN3-CA	NWLSdJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofPTWM2OD14Lk[4OlQyKM7:TR?=	NUTMPYJPW0GQR1XS
Calu-6	Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3md\|lZUUN3ME22Mlc6Pjl6IN88US=>	MVjTRW5ITVJ?
HCT-116	M{LOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH22fldKSzVyPU[uPFEzPjRizszN	M2T4TnNCVkeHUh?=
MHH-NB-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTkcVZ[UUN3ME22Mlg2ODB{IN88US=>	Mmf2V2FPT0WU
MFE-280	NVrsV2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\NTWM2OD14Lki1PVg{KM7:TR?=	MWXTRW5ITVJ?
SW1088	M4XJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj0TWM2OD14LkmxPVE{KM7:TR?=	NXnYPYN4W0GQR1XS
SW48	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuwcYUxUUN3ME22Mlk1PTFizszN	MnH5V2FPT0WU
HuCCT1	NXP0boYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvCVoczUUN3ME23MlAyODN5IN88US=>	NGLROFlUSU6JRWK=
ACHN	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTdwMEK5OFMh\|ryP	M1nVWHNCVkeHUh?=
8305C	NGK1W2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj6e2tKSzVyPUeuNFk6QTVizszN	NF;UdXhUSU6JRWK=
DoTc2-4510	MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH6TWM2OD15LkGyNVUh\|ryP	MUnTRW5ITVJ?
COR-L23	NH36botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVGxeGZZUUN3ME23MlI1PDJizszN	NE\xSXFUSU6JRWK=
SK-MEL-30	M3u1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTdwMkWwPFMh\|ryP	NGG5VWhUSU6JRWK=
BE-13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4C3NGlEPTB;Nz6zN\|g{PCEQvF2=	M3zKRXNCVkeHUh?=
GR-ST	M134XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjWTWM2OD15LkSwNVc1KM7:TR?=	NYXubW9UW0GQR1XS
LU-135	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\USGViUUN3ME23MlU2QTN7IN88US=>	NEm1dFZUSU6JRWK=
U-266	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\CbFFKSzVyPUeuOVYzQDZizszN	M2CxTXNCVkeHUh?=
NCI-H1355	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHEUXoyUUN3ME23MlU5PjN3IN88US=>	MW\TRW5ITVJ?
NB14	NInXZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml34TWM2OD15Lk[2OlQzKM7:TR?=	Ml7PV2FPT0WU
SCC-25	NVfqVVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTiO5ZqUUN3ME23MlcxQSEQvF2=	M2HGVXNCVkeHUh?=
COLO-678	M4XVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFezRVhKSzVyPUeuO\|ExPzZizszN	MVrTRW5ITVJ?
TGBC1TKB	NILjXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O3[GlEPTB;Nz64PVM6QCEQvF2=	MlLtV2FPT0WU
IST-MEL1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDjRmlKSzVyPUiuNFA1ODZizszN	Ml\iV2FPT0WU
ECC10	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXodWZKSzVyPUiuNFM{QTVizszN	MXfTRW5ITVJ?
EW-16	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O3OmlEPTB;OD6wPFQ1PSEQvF2=	MlSwV2FPT0WU
DOHH-2	M1G4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRThwMkCwPVUh\|ryP	NWnTdVdsW0GQR1XS
NCI-H1581	NUe3XYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zDb2lEPTB;OD6yOlMzOyEQvF2=	M3vwXXNCVkeHUh?=
TE-5	NGXNeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxfJBxUUN3ME24MlQzPDJ7IN88US=>	Ml;sV2FPT0WU
CAKI-1	NVr5bGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRThwNUeyNlIh\|ryP	M{HCZ3NCVkeHUh?=
A673	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRThwNkOyNFIh\|ryP	NV75PHBbW0GQR1XS
CAL-12T	NF34N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHkUpJKSzVyPUiuOlU4PTNizszN	MlGxV2FPT0WU
DBTRG-05MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHFSnRKSzVyPUiuO\|Q5PTlizszN	M3TibXNCVkeHUh?=
SK-N-FI	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nDN2lEPTB;OD64NVM4QSEQvF2=	MVPTRW5ITVJ?
K-562	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRThwOEO5OVch\|ryP	MmnBV2FPT0WU
SBC-1	NFTXUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nWe2lEPTB;OD64OlY1PSEQvF2=	MlrTV2FPT0WU
ES4	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjRNpJmUUN3ME24Mlg3QDh2IN88US=>	MXXTRW5ITVJ?
MS-1	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRThwOEe1NVch\|ryP	MnjoV2FPT0WU
RKO	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnFZlEyUUN3ME24Mlg6ODV5IN88US=>	NHz4elNUSU6JRWK=
NCI-H1693	NXu5bIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRThwOUKxO{DPxE1?	MXfTRW5ITVJ?
SW954	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLpTWM2OD16Lkm2PVc5KM7:TR?=	NYjwXWlpW0GQR1XS
SK-UT-1	NYjDNZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIKwSlVKSzVyPUiuPVc3QDNizszN	NHz4VmdUSU6JRWK=
T98G	NWPydG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13RdWlEPTB;OD65PVg1PiEQvF2=	NYnjNXRPW0GQR1XS
NCI-H2126	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkWxTWM2OD17LkCwPFI3KM7:TR?=	M1T5enNCVkeHUh?=
TE-12	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTlwMEOzOlch\|ryP	MnHtV2FPT0WU
DK-MG	NEfOeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrmNWtKSzVyPUmuNlEyQTFizszN	M4nBfnNCVkeHUh?=
MEG-01	NIDXXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TsV2lEPTB;OT6yOFk{OSEQvF2=	NF74d45USU6JRWK=
HCC1937	NGS0XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTSVGNKSzVyPUmuNlkxQTFizszN	Mnu3V2FPT0WU
MKN45	M3Hzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j4dmlEPTB;OT60OVA3PSEQvF2=	Mlv3V2FPT0WU
NCI-H1792	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PUbGlEPTB;OT60OVIyQSEQvF2=	NUHFRYxGW0GQR1XS
SW1417	M2LVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzJTWM2OD17LkW2PFM4KM7:TR?=	M13TO3NCVkeHUh?=
639-V	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjlTHV3UUN3ME25MlY1Ozh6IN88US=>	MkHlV2FPT0WU
P30-OHK	NIm0PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33TUWlEPTB;OT62OVMyPiEQvF2=	NVjaXoNKW0GQR1XS
YKG-1	NEjZWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm0OXdGUUN3ME25Mlc2ODN\|IN88US=>	NHTFOXJUSU6JRWK=
KGN	NWPIToc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTlwOEO3PVUh\|ryP	MoLkV2FPT0WU
MSTO-211H	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TSeWlEPTB;OT65OVUzQSEQvF2=	NWDnUJkzW0GQR1XS
NCI-H1573	NG\2cGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFyLkG1O\|Qh\|ryP	NYfFOG45W0GQR1XS
NCI-H720	NH7nWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TqR2lEPTB;MUCuNVk5QSEQvF2=	MkjyV2FPT0WU
KARPAS-45	M{Xje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXQcJVKSzVyPUGwMlI4QTVizszN	NEj4R3dUSU6JRWK=
MDA-MB-175-VII	MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPXdm5DUUN3ME2xNE41QCEQvF2=	NHvRNHhUSU6JRWK=
SK-NEP-1	NE[yO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHiTWM2OD1zMD60PVgyKM7:TR?=	NFe5eZNUSU6JRWK=
MKN28	NVWxZYZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrOTWM2OD1zMD61NVgh\|ryP	MnvoV2FPT0WU
KYSE-520	NW\IPHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPCTWM2OD1zMD61NkDPxE1?	M1uyV3NCVkeHUh?=
KE-37	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFyLkWyO\|Ih\|ryP	M1zkSnNCVkeHUh?=
VA-ES-BJ	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHlWGFUUUN3ME2xNE42PjdizszN	M{\BW3NCVkeHUh?=
CCRF-CEM	NXewe3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nURWlEPTB;MUCuOVY5PCEQvF2=	NVOzPHRjW0GQR1XS
GMS-10	M3:ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnqRWx[UUN3ME2xNE43ODl2IN88US=>	M{S1cXNCVkeHUh?=
NCI-H1623	NWjMWnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;SdHh{UUN3ME2xNE43Ozd7IN88US=>	NYixZ5M5W0GQR1XS
NEC8	M1XIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{WwUGlEPTB;MUCuO\|c4OyEQvF2=	MX3TRW5ITVJ?
MOLT-16	M4SyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFyLkixNVMh\|ryP	MYDTRW5ITVJ?
DJM-1	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofjTWM2OD1zMT6wN\|c6KM7:TR?=	MoLEV2FPT0WU
U251	M4HMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGKz[olKSzVyPUGxMlA1OiEQvF2=	MUDTRW5ITVJ?
SBC-5	NUHuW5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXJW45xUUN3ME2xNU4yPDZ5IN88US=>	NYC0XohJW0GQR1XS
SW756	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mof4TWM2OD1zMT6yNVU1KM7:TR?=	NGjBXY9USU6JRWK=
KS-1	NH7lbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4f5bGlEPTB;MUGuNlYyQSEQvF2=	NXPRbosyW0GQR1XS
SF295	NX7yN3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f6SmlEPTB;MUGuN\|ExPCEQvF2=	MlHVV2FPT0WU
YH-13	NYru[3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTFzLkOyOlch\|ryP	NXLSfVlCW0GQR1XS
SW837	NUj3NY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\QTGlEPTB;MUGuN\|UxPiEQvF2=	M{naV3NCVkeHUh?=
KYSE-450	M2G0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTFzLkSwOVch\|ryP	MkKxV2FPT0WU
KYSE-180	NIGzbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPUO4RYUUN3ME2xNU41QDJizszN	MoLmV2FPT0WU
S-117	M1HZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnjdVU4UUN3ME2xNU41QDl4IN88US=>	NIW5NphUSU6JRWK=
KOSC-2	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTFzLk[yNlIh\|ryP	Mlf5V2FPT0WU
KYSE-270	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnwSm4yUUN3ME2xNU45PzR3IN88US=>	NUD2boQ6W0GQR1XS
D-336MG	NEj0e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLtTWM2OD1zMT65NFc2KM7:TR?=	MlTaV2FPT0WU
KALS-1	NHezXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorMTWM2OD1zMj6wNFE3KM7:TR?=	NEH0enpUSU6JRWK=
LB373-MEL-D	NUPZSYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TB[WlEPTB;MUKuNFU{OyEQvF2=	M13PeHNCVkeHUh?=
HLE	NHznfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDHTWM2OD1zMj6wOVg2KM7:TR?=	NFjPSm1USU6JRWK=
SJSA-1	M{jQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f4TWlEPTB;MUKuNFc{PSEQvF2=	M4fZXHNCVkeHUh?=
SW1990	M3\6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPJXHM4UUN3ME2xNk4xQTFzIN88US=>	MV\TRW5ITVJ?
NOS-1	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3pUYdKSzVyPUGyMlE{PTJizszN	NXv2VlRGW0GQR1XS
GI-ME-N	M1nqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrt[XBbUUN3ME2xNk4zOTZ\|IN88US=>	NHrHV2JUSU6JRWK=
NCI-H1703	NHLCNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;hTWM2OD1zMj6yOlE3KM7:TR?=	Mn7xV2FPT0WU
ES7	NXXsfnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHHUGpIUUN3ME2xNk4zPzJ2IN88US=>	MmeyV2FPT0WU
KYSE-510	NWjiUFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\NZW1lUUN3ME2xNk42ODd7IN88US=>	NVG3[HRnW0GQR1XS
BHY	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HwNmlEPTB;MUKuOVMxPyEQvF2=	MVfTRW5ITVJ?
TCCSUP	NEnmb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj6W4ZKSzVyPUGyMlU4PTdizszN	MXnTRW5ITVJ?
HSC-2	NUezTnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NViyOpN[UUN3ME2xNk42QTl4IN88US=>	NGDubFdUSU6JRWK=
BEN	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF{Lk[xOFMh\|ryP	MXTTRW5ITVJ?
769-P	NIm3XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fGeGlEPTB;MUKuO\|kzPCEQvF2=	MoiwV2FPT0WU
HT	MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDhTWM2OD1zMj64N\|Q3KM7:TR?=	NVjSeoE1W0GQR1XS
LXF-289	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfNO2ZTUUN3ME2xNk46PTNzIN88US=>	MXfTRW5ITVJ?
OVCAR-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jTR2lEPTB;MUKuPVU3PyEQvF2=	MmrRV2FPT0WU
ATN-1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofrTWM2OD1zMz6wNVg1KM7:TR?=	NEnmNVlUSU6JRWK=
8-MG-BA	NGWxd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn34TWM2OD1zMz6wOFU2KM7:TR?=	MnLlV2FPT0WU
SW13	NUjVepFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTF\|LkGxOlUh\|ryP	NIr5cItUSU6JRWK=
NCI-H1092	NUK5em9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\FTWM2OD1zMz6xOlIh\|ryP	MlLPV2FPT0WU
OAW-42	M{TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPa[5FKSzVyPUGzMlE6OzdizszN	NELle4JUSU6JRWK=
NCI-H2452	NV3TUlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLHSY1KSzVyPUGzMlIyPzVizszN	M1nDRXNCVkeHUh?=
CAPAN-1	M3To[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;3bWlEPTB;MUOuOVUyPCEQvF2=	NXzVVHdPW0GQR1XS
NCI-H2009	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF\|LkW5NVkh\|ryP	MlrEV2FPT0WU
SF268	M1v0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDt[YFFUUN3ME2xN{43OzJ4IN88US=>	MYHTRW5ITVJ?
GCIY	M4\mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLtTWM2OD1zMz62PVI4KM7:TR?=	MXTTRW5ITVJ?
OS-RC-2	NVvtTGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTZTWM2OD1zMz65OVAyKM7:TR?=	MmfqV2FPT0WU
GCT	NEP3SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXKc4pGUUN3ME2xN{46Pjl5IN88US=>	M{fIenNCVkeHUh?=
NB17	NWHPe3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37B[WlEPTB;MUSuNFg2KM7:TR?=	NYftTWp5W0GQR1XS
NCI-H2030	M2O2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHOTWM2OD1zND6xOFY2KM7:TR?=	NVfMUpFzW0GQR1XS
HC-1	NVPicGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjldWE6UUN3ME2xOE4zODh5IN88US=>	M{n1ZXNCVkeHUh?=
QIMR-WIL	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rDbGlEPTB;MUSuN\|QyOiEQvF2=	MnjmV2FPT0WU
Capan-2	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFOy[JBKSzVyPUG0MlM4OTRizszN	NIPXOlhUSU6JRWK=
BALL-1	NV;ZS3NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvRZZFKSzVyPUG0MlQ3PjVizszN	Mm\rV2FPT0WU
LS-1034	NUKzUGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jKc2lEPTB;MUSuOlE2OiEQvF2=	NX31WJlMW0GQR1XS
U-118-MG	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTF2Lk[zNUDPxE1?	MlO0V2FPT0WU
NCI-H630	NGLGU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTLOG1JUUN3ME2xOE43PTZ6IN88US=>	Mmq1V2FPT0WU
OVCAR-8	M2\MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TwWmlEPTB;MUSuO\|IxOSEQvF2=	NYTqWXJjW0GQR1XS
NCI-H2347	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjrTWM2OD1zND64NlMh\|ryP	NETjZpFUSU6JRWK=
BT-549	NHHHVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfNe4htUUN3ME2xOE45Ojh2IN88US=>	M4XzbHNCVkeHUh?=
LB831-BLC	NIizXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLmTWM2OD1zND64PVM1KM7:TR?=	MkjkV2FPT0WU
NCI-H661	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjoTWM2OD1zND65OVkh\|ryP	NW\BUnplW0GQR1XS
MKN7	M2rydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\ITWM2OD1zNT6wNFk{KM7:TR?=	MmrJV2FPT0WU
U-87-MG	M1nkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D2ZmlEPTB;MUWuNFg6PyEQvF2=	NEjwe45USU6JRWK=
OVCAR-4	M4\kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MniyTWM2OD1zNT6xOFI1KM7:TR?=	NVHtcJNSW0GQR1XS
OE33	NWHk[FE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjnb4dKSzVyPUG1MlE4OTFizszN	NXjoepAzW0GQR1XS
EC-GI-10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFqyfnRKSzVyPUG1MlI{PTdizszN	M17vZnNCVkeHUh?=
AM-38	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTRd\|k{UUN3ME2xOU4zPzF5IN88US=>	NW\MXo9{W0GQR1XS
NCI-H1563	NHj0O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTjPWVEUUN3ME2xOU4{PDlizszN	M1vWPXNCVkeHUh?=
SCC-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjjenZPUUN3ME2xOU41OTB\|IN88US=>	NW\ubmFPW0GQR1XS
Detroit562	MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTF3LkS1OFch\|ryP	NIrTbYZUSU6JRWK=
PC-14	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7tRlFKSzVyPUG1MlQ5PjZizszN	NHnGWGVUSU6JRWK=
ES3	NGTVNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGzWpN3UUN3ME2xOU42OzZizszN	NHvsO4xUSU6JRWK=
OCI-AML2	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HpWmlEPTB;MUWuO\|YyPCEQvF2=	NXzNfWFFW0GQR1XS
LU-134-A	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvOTWM2OD1zNT65NFE5KM7:TR?=	NXnBSJlIW0GQR1XS
SAS	NG\tbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnOVJZKSzVyPUG1Mlk{PzNizszN	NGf3dFVUSU6JRWK=
TGBC11TKB	M4TJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7pfVVDUUN3ME2xOU46PDF2IN88US=>	NGW1SoRUSU6JRWK=
HOP-62	NX\GVnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjF[pVwUUN3ME2xOU46PTl5IN88US=>	MmLRV2FPT0WU
G-401	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXBc3VMUUN3ME2xOU46PjR7IN88US=>	NHKydZVUSU6JRWK=
NCI-H28	NUDLRWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml72TWM2OD1zNj6wPFU3KM7:TR?=	MkDvV2FPT0WU
A204	NXjiTZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofWTWM2OD1zNj6yNFA3KM7:TR?=	NWDMTmZ7W0GQR1XS
NCI-H1299	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTF4LkKyPVEh\|ryP	MoLRV2FPT0WU
VMRC-RCZ	NFfzT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf3UVJKSzVyPUG2MlI2QTJizszN	M1jORXNCVkeHUh?=
BxPC-3	NU\zPGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\wS2lEPTB;MU[uNlg2PiEQvF2=	NWX4[XUxW0GQR1XS
NCI-H2228	M{KySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3HTYxKSzVyPUG2MlUyPThizszN	NXHveHdCW0GQR1XS
NCI-H23	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTF4Lk[wO\|gh\|ryP	M4\FbXNCVkeHUh?=
NKM-1	NULJfZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHW4UHhKSzVyPUG3MlAyQDlizszN	NU\WR4loW0GQR1XS
KYSE-70	NXHKe\|FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlG2TWM2OD1zNz6yPFkh\|ryP	M3PRW3NCVkeHUh?=
BB49-HNC	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\ic2lEPTB;MUeuOVY5PiEQvF2=	M3W1UXNCVkeHUh?=
SCC-15	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzIcmtJUUN3ME2xO{45PDd\|IN88US=>	NHnCXY1USU6JRWK=
D-247MG	NITCUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XKb2lEPTB;MUeuPVI1PyEQvF2=	MV;TRW5ITVJ?
BB30-HNC	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\mXIlKSzVyPUG4MlA{OThizszN	NHLr[ZhUSU6JRWK=
CAL-85-1	M1niTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnvTWM2OD1zOD6xPFA6KM7:TR?=	NF\zWHdUSU6JRWK=
HT-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV34O5RqUUN3ME2xPE4{QTd5IN88US=>	NF3JO2lUSU6JRWK=
KYSE-410	NYj5[odjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Phe2lEPTB;MUiuOFU4PyEQvF2=	NV3wdHJVW0GQR1XS
SW982	NVOwN5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mli4TWM2OD1zOD61OlQ6KM7:TR?=	MonRV2FPT0WU
SW962	NHrPZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTF6LkW3NFIh\|ryP	M36xbHNCVkeHUh?=
Ramos-2G6-4C10	MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD3OotFUUN3ME2xPE42QTJ5IN88US=>	MY\TRW5ITVJ?
OC-314	NULCfo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTF6LkezPFQh\|ryP	Mnf5V2FPT0WU
LS-123	M4PWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTF6Lke5NFEh\|ryP	MUfTRW5ITVJ?
D-502MG	NXyydYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDKTWM2OD1zOD64NVM6KM7:TR?=	NVfjd4w6W0GQR1XS
RO82-W-1	NYeyRXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\GTWM2OD1zOD64Nlg5KM7:TR?=	Mn7JV2FPT0WU
HuO9	M1ntfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\XUnJKSzVyPUG5MlE{PzlizszN	Mn7KV2FPT0WU
ETK-1	NFjFZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTF7LkG4Nlch\|ryP	NHvKZ2dUSU6JRWK=
SNU-387	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M131O2lEPTB;MUmuNVg5QSEQvF2=	NXr6c5hTW0GQR1XS
SW1573	NHTHOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XxNGlEPTB;MUmuNVk3QSEQvF2=	MWPTRW5ITVJ?
NTERA-S-cl-D1	NIm5OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TwcWlEPTB;MUmuNlAxPyEQvF2=	MWLTRW5ITVJ?
SF126	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETsd\|VKSzVyPUG5MlM2ODJizszN	MmS1V2FPT0WU
Calu-3	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF7LkSyN\|ch\|ryP	M1\X[XNCVkeHUh?=
NCI-H1048	NUD4bmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjEOVhKSzVyPUKwMlMzPjZizszN	M1jsSXNCVkeHUh?=
NCI-H226	M1u3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJyLkSzPVkh\|ryP	NIPhXlFUSU6JRWK=
FTC-133	NGS1RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\zUmNKSzVyPUKwMlQ4ODNizszN	MlXOV2FPT0WU
SF539	M{PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnCOI16UUN3ME2yNE42OTd{IN88US=>	M1HTbXNCVkeHUh?=
TE-6	M2\5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXNTWM2OD1{MD64NFY4KM7:TR?=	MV\TRW5ITVJ?
UMC-11	NVP0R3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjQ[YJuUUN3ME2yNE46OTZ2IN88US=>	MVTTRW5ITVJ?
Becker	NG\qd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnntTWM2OD1{MT6xNVE5KM7:TR?=	MmjnV2FPT0WU
KP-4	NFXG[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXjTWM2OD1{MT6xNVk3KM7:TR?=	NYrQZXY6W0GQR1XS
ChaGo-K-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXv[VZKSzVyPUKxMlM3OjdizszN	MVvTRW5ITVJ?
CFPAC-1	NF\tS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrIU2dKSzVyPUKxMlM5PThizszN	M1jLe3NCVkeHUh?=
A498	M2T3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfWT3BoUUN3ME2yNU42OzF{IN88US=>	Ml63V2FPT0WU
NCI-H1755	NHX6[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37KPWlEPTB;MkGuOlc1OSEQvF2=	NV\RWnZKW0GQR1XS
TI-73	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe2WGRzUUN3ME2yNk4{OjhizszN	MXrTRW5ITVJ?
NCI-H441	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHteJFKSzVyPUKyMlU3QDlizszN	NHrCRYxUSU6JRWK=
CaR-1	M4m0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTJ\|LkCyNVMh\|ryP	M4nidHNCVkeHUh?=
HCC1806	NFrqRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Ls[GlEPTB;MkOuNFU5OyEQvF2=	MXnTRW5ITVJ?
SNU-449	NXzCO\|F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPhWYtCUUN3ME2yN{4{OjlizszN	MlPDV2FPT0WU
EKVX	NVW3c3BMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki5TWM2OD1{Mz6zPVA6KM7:TR?=	M1PHRnNCVkeHUh?=
DMS-114	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPkZWRFUUN3ME2yN{42PzZ3IN88US=>	NFfHPVNUSU6JRWK=
A704	NX:yb\|hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XpdWlEPTB;MkOuOlExOyEQvF2=	M{fTPHNCVkeHUh?=
LC-2-ad	M4H1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJ\|Lk[xOFch\|ryP	NX\LNGdzW0GQR1XS
VM-CUB-1	NUnv[3BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moe5TWM2OD1{Mz63N\|QyKM7:TR?=	MXjTRW5ITVJ?
PC-3	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TZbWlEPTB;MkSuNFUzPiEQvF2=	MYLTRW5ITVJ?
HEL	NFT2OWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPLUldyUUN3ME2yOE4xQDZ3IN88US=>	MUDTRW5ITVJ?
ABC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXzToNqUUN3ME2yOE4zPzJ7IN88US=>	NVGwZnFCW0GQR1XS
COLO-680N	NUS4V4hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PlfmlEPTB;MkSuOFc3PCEQvF2=	Mln0V2FPT0WU
MZ1-PC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTvTWM2OD1{ND62PFch\|ryP	NIHi[4pUSU6JRWK=
NCI-H69	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ixN2lEPTB;MkSuO\|M2PCEQvF2=	M4jTVXNCVkeHUh?=
TE-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPaUIdKSzVyPUK1MlA1QTlizszN	NH:4doRUSU6JRWK=
EW-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTKTWM2OD1{NT6xNVMh\|ryP	MnS1V2FPT0WU
PANC-08-13	NXrhbpU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTETWM2OD1{NT64NVA{KM7:TR?=	M4XqbnNCVkeHUh?=
NMC-G1	M2DKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjIZmpuUUN3ME2yOk4xODh6IN88US=>	MYHTRW5ITVJ?
BT-20	NHLPWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTvcXJ2UUN3ME2yOk41PTR\|IN88US=>	NILJZWxUSU6JRWK=
TGBC24TKB	MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zOcmlEPTB;Mk[uO\|M{OSEQvF2=	NIDzR45USU6JRWK=
TE-11	NYjvV4N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJ4Lkm4PVUh\|ryP	M3\NdXNCVkeHUh?=
ESS-1	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO0dnRKSzVyPUK3MlMzOTZizszN	NHHwW45USU6JRWK=
JVM-3	NV7Uc4d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrYNodRUUN3ME2yO{43PDd3IN88US=>	MVHTRW5ITVJ?
C3A	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHxcGFsUUN3ME2yO{45PDl4IN88US=>	M4q1dnNCVkeHUh?=
MDA-MB-157	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXG5fXNKUUN3ME2yO{45PzV\|IN88US=>	MXfTRW5ITVJ?
KLE	NGGxXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPITWM2OD1{OD6xNFU5KM7:TR?=	NXfaZoZYW0GQR1XS
ES1	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojQTWM2OD1{OD6xPFM5KM7:TR?=	NFm1T\|FUSU6JRWK=
CAL-120	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LSemlEPTB;MkiuN\|k6QSEQvF2=	MkLFV2FPT0WU
NCI-N87	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG1TWM2OD1{OD61NVA2KM7:TR?=	NHez[FdUSU6JRWK=
RPMI-8226	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVryNWUzUUN3ME2yPU4yQDR\|IN88US=>	MWXTRW5ITVJ?
COR-L88	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJ7LkK0NVkh\|ryP	NYD0cHhRW0GQR1XS
UACC-893	NEnwXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnETWM2OD1{OT6zNVM4KM7:TR?=	M{L3d3NCVkeHUh?=
C8166	M3zy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXxV4lZUUN3ME2yPU46QTl4IN88US=>	M4W3RXNCVkeHUh?=
J82	NWTFS2RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTNyLkixOFch\|ryP	MVzTRW5ITVJ?
PFSK-1	NFO1fIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;afZRKSzVyPUOxMlA3PTlizszN	NF3LbGVUSU6JRWK=
COLO-684	NH20ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrPOWxzUUN3ME2zNU41Ozd2IN88US=>	NITnVWtUSU6JRWK=
CAL-72	NGTVU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[0RllUUUN3ME2zNU42PzJ7IN88US=>	NYjCb4o5W0GQR1XS
SNB75	M2TRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTQTWM2OD1\|MT64PVch\|ryP	NFzzfWVUSU6JRWK=
MDA-MB-415	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX6NoxKSzVyPUOxMlk4PjJizszN	NITBRZBUSU6JRWK=
SiHa	M4T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX5TWM2OD1\|Mj60O\|EyKM7:TR?=	NUHheIYxW0GQR1XS
NCI-H1648	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\lTWM2OD1\|Mj65N\|Q2KM7:TR?=	MlPSV2FPT0WU
EFO-21	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\vSGlEPTB;M{OuNFA2KM7:TR?=	MnHBV2FPT0WU
HCC38	NV3iRW03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDlTWM2OD1\|Mz6zPFQyKM7:TR?=	NYnwVoVpW0GQR1XS
IA-LM	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTITWM2OD1\|Mz63PFg6KM7:TR?=	MU\TRW5ITVJ?
CTV-1	NXu3U4d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXONVhKSzVyPUOzMlk4QDZizszN	NXPyXWJCW0GQR1XS
NCI-H446	NXzlVnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17FV2lEPTB;M{SuNlY5QSEQvF2=	NWi1NlIzW0GQR1XS
IST-SL1	NWfOWJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fnZ2lEPTB;M{SuO\|QxQCEQvF2=	M{P0bXNCVkeHUh?=
EW-22	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTN2Lke3OVkh\|ryP	M3zRWXNCVkeHUh?=
JEG-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETHVZlKSzVyPUO2MlE4PjZizszN	NYOwSHI3W0GQR1XS
LU-65	NInjdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTN4LkK5PFUh\|ryP	NGX4UYhUSU6JRWK=
NCI-H596	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor0TWM2OD1\|Nj65OVkyKM7:TR?=	NUfqS5FrW0GQR1XS
KNS-81-FD	M3LZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzmZ4VJUUN3ME2zO{4yPDVizszN	MkXKV2FPT0WU
NCI-H1793	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDFO\|BKSzVyPUO3MlcxQDZizszN	NFLaW5dUSU6JRWK=
NCI-H460	NGTpXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPQ[HQ4UUN3ME2zPE4xQDd\|IN88US=>	NF\hRpZUSU6JRWK=
MPP-89	M17vZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTN7LkW4PFYh\|ryP	MmTEV2FPT0WU
D-542MG	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvaTWM2OD1\|OT64OFM3KM7:TR?=	M3rld3NCVkeHUh?=
JAR	NEjGWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXzdWdKSzVyPUSwMlQ4ODVizszN	M33YbXNCVkeHUh?=
NCI-H209	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\Z[ZlUUUN3ME20NE43PzdizszN	NHjU[FhUSU6JRWK=
G-402	M2nBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf3doxKSzVyPUSxMlM6QTNizszN	M1zF[nNCVkeHUh?=
IST-MES1	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv4TWM2OD12Mj6xPVM2KM7:TR?=	M4rGUXNCVkeHUh?=
Daoy	M1jjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFj4VJRKSzVyPUSyMlU1PzFizszN	MWLTRW5ITVJ?
EW-11	M{LQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzDTWM2OD12Mz6xNlEyKM7:TR?=	NXvJSHl4W0GQR1XS
Saos-2	NG\FS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3BTWM2OD12Mz6xOVM4KM7:TR?=	Mnu5V2FPT0WU
no-10	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfUNmV2UUN3ME20N{4yPzB{IN88US=>	MorhV2FPT0WU
HCC1395	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm0TWM2OD12Mz60OlQ1KM7:TR?=	NUX2Xo9mW0GQR1XS
HCE-4	M4XEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTR\|Lke2OlQh\|ryP	M4rC[HNCVkeHUh?=
EW-1	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfYUHNKSzVyPUSzMlgxPDlizszN	Ml\PV2FPT0WU
OCUB-M	MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\IS4NHUUN3ME20OE4{PjN6IN88US=>	MkjnV2FPT0WU
IGR-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPteoxKSzVyPUS0MlQyOTVizszN	MlSxV2FPT0WU
NCI-H1838	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;RT20zUUN3ME20OE41OzR7IN88US=>	MnTDV2FPT0WU
NCI-H2405	NInBWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr5T3ZKSzVyPUS0MlU{PCEQvF2=	NHTI[mxUSU6JRWK=
GB-1	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHjdmZ7UUN3ME20OE44PDZ\|IN88US=>	M4XBbnNCVkeHUh?=
MG-63	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\XPZpKSzVyPUS2MlA3QTZizszN	MnnmV2FPT0WU
KP-N-YN	NHr3UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTR4LkS2O\|kh\|ryP	M1fGNnNCVkeHUh?=
no-11	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRcmlEPTB;NEeuNFI1PCEQvF2=	M1zlVnNCVkeHUh?=
SW948	M4\OcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTR5LkOzO\|ch\|ryP	MULTRW5ITVJ?
CAMA-1	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESyVZVKSzVyPUS3MlM1OzhizszN	M3LCcHNCVkeHUh?=
HCC1187	NEHXToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPT[\|dKSzVyPUS3MlUyKM7:TR?=	NILjSGRUSU6JRWK=
D-392MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG2TWM2OD12Nz62OVE3KM7:TR?=	NFrSfXdUSU6JRWK=
647-V	M2rJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17JfmlEPTB;NEmuN\|QyPCEQvF2=	MmHsV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK1/2 / ERK1/2 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK1/2 in sympathetic neurons. Immunoblots were performed with whole cell extracts from sympathetic neurons maintained in the presence of NGF and left untreated or treated with PD184352 at 0.1, 1, 2 or 10 μM for 16 hours. Antibodies to detect total ERK1/2 and phospho-ERK1/2 were used. p-ERK5 / ERK5 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK5 in sympathetic neurons.	21762482
Growth inhibition assay	Cell viability; PubMed: 29989268 Cancer Sci Relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells in WST assay.	29989268

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	- Collapse MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	- Collapse Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901(Mirdametinib)

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 78 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 78 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)